Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20–mutant NSCLC: case report
EGFR exon 20 insertion mutations represent a distinct subset of non–small cell lung cancer (NSCLC) with limited sensitivity to earlier-generation EGFR tyrosine kinase inhibitors (TKIs). CLN081 (zipalertinib; TAS6417) is a novel covalent EGFR TKI under development with activity against EGFR exon 20 insertion variants. W...